Highwise Health
U.S.

FDA to Discuss Future Trial for DLB Psychosis Drug

Regulators will review plans for a potential study of zervimesine to treat psychosis symptoms in patients with DLB.

Updated on Sept. 29, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a laboratory beaker, representing scientific analysis and regulatory review for a new dementia drug.
The FDA will meet with Cognition Therapeutics on October 20 to finalize the trial design for zervimesine, a potential treatment for DLB-associated psychosis. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies prioritize developing treatments for psychosis symptoms in neurodegenerative disease patients?

Cognition Therapeutics has scheduled a Type C meeting with the FDA for October 20, 2026, to discuss the design of a registrational trial for the drug zervimesine. The trial would evaluate the efficacy of the treatment for psychosis in patients with dementia with Lewy bodies (DLB).

Why it matters

Up to 80% of people with DLB experience psychosis, yet there are currently no FDA-approved medications specifically for treating these symptoms. Aligning on trial endpoints is a critical step toward potentially bringing the first dedicated therapy to this patient population.

In a Phase 2 trial, zervimesine demonstrated an 89% reduction in the progression of hallucinations and delusions compared to placebo. The proposed Phase 3 study design intends to test a 100 mg daily oral dose against a placebo over a nine-month period.

The players

Cognition Therapeutics

A company based in Purchase, New York, focused on developing treatments for neurodegenerative conditions like DLB.

FDA Division of Neurology

The regulatory body within the United States that oversees the approval and testing standards for neurological therapies.

The details

Zervimesine is being developed as a potential intervention to address neuropsychiatric symptoms in DLB, a condition where protein deposits build up in the brain. The upcoming FDA meeting will focus on the statistical details for a planned trial that would allow participants to enroll regardless of their background medication use. Establishing these analytical parameters is necessary to secure regulatory approval for a treatment targeting this specific, high-need symptom profile.

Timeline

  1. June 2026: Cognition Therapeutics received previous meeting minutes from the FDA.

  2. September 29, 2026: The company announced the upcoming October 20, 2026, meeting.

  3. October 20, 2026: The FDA Type C meeting is scheduled to occur.

Health Landscape

This development marks a significant move in the clinical landscape for DLB, a condition that currently lacks any approved pharmaceutical treatments. Cognition Therapeutics has received nearly $200 million in NIH and foundation grants to advance this research toward a registrational trial.

Because there are currently no approved drugs for DLB-related psychosis, caregivers should keep track of emerging trial data and discuss potential study eligibility with a neurologist. Managing these symptoms is often complex, and any changes in care or participation in clinical trials should be coordinated with a patient's primary care team.

The takeaway

The lack of approved therapies for DLB psychosis makes the progress of zervimesine a development worth monitoring for those affected by the condition. Patients and families can consult with a neurologist about the symptoms of psychosis to ensure current management strategies remain appropriate.

Further reading

Learn more about the latest research and clinical landscape for patients and caregivers in our Alzheimer’s section.

Live Poll

Should pharmaceutical companies prioritize developing treatments for psychosis symptoms in neurodegenerative disease patients?